Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2014 Apr 11;145(2):389–399. doi: 10.1007/s10549-014-2945-3

Table 2.

Patient and tumor characteristics of the total cohort and by PIK3CA mutation status.

Characteristic Total cohort
(N = 312)
Wild type
(N= 233)
PIK3CA Mutated
(N = 79)
P value*
N (%) N (%) N (%)
Age
≤ 50 130 (42%) 106 (45%) 24 (30%)
> 50 164 (53%) 113 (48%) 51 (65%) 0.014
Unknown 18 (6%) 14 (1%) 4 (1%)
Menopausal status
Pre 84 (27%) 66 (28%) 18 (23%)
Post 77 (25%) 51 (22%) 26 (33%) 0.079
Unknown 151 (49%) 116 (50%) 35 (44%)
Race
Caucasian 268 (86%) 197 (85%) 71 (90%)
Black 27 (9%) 24 (10%) 3 (4%)
Asian/Pacific Islander 2 (1%) 2 (0.1%) 0 (0%) 0.178
Unknown or other 15 (5%) 10 (4%) 4 (5%)
Tumor size
0 – 2 cm 76 (24%) 58 (25%) 18 (23%)
2.1 – 5 cm 75 (24%) 56 (24%) 19 (24%)
> 5 cm 19 (6%) 16 (7%) 3 (4%) 0.74
Unknown or NA 142 (46%) 103 (44%) 39 (49%)
Positive lymph nodes
0 107 (34%) 75 (32%) 32 (41%)
1 – 3 91 (29%) 71 (30%) 20 (25%)
> 3 65 (21%) 50 (21%) 15 (19%) 0.39
NA 49 (16%) 37 (16%) 12 (15%)
Histologic subtype
Ductal 283 (91%) 211 (93%) 72 (92%)
Lobular 12 (4%) 8 (4%) 4 (5%)
Other 17 (5%) 8 (4%) 2 (3%) 0.74
Histologic Grade
Low 40 (13%) 23 (10%) 17 (22%)
Intermediate 122 (39%) 80 (34%) 42 (53%)
High 143 (46%) 124 (53%) 19 (24%) < 0.001
Unknown or NA 7 (2%) 6 (3%) 1 (1%)
ER
Postive 208 (67%) 142 (61%) 66 (84%)
Negative 93 (30%) 85 (36%) 8 (8%) < 0.001
Unknown 11 (4%) 6 (3%) 5 (6%)
PR
Positive 175 (56%) 119 (51%) 56 (71%)
Negative 122 (39%) 105 (45%) 17 (22%) <0.001
Unknown 15 (5%) 9 (4%) 6 (8%)
HER2
Positive 52 (17%) 47 (20%) 6 (8%)
Negative 233 (75%) 171 (73%) 62 (78%) 0.008
Intedeterminate or unknown 26 (8%) 15 (6%) 11 (14%)
Receptor status
ER+ or PR+/HER2− 169 (54%) 113 (48%) 56 (71%)
ER+ or PR+/HER2+ 30 (10%) 27 (12%) 3 (4%)
ER−and PR−/HER2+ 21 (7%) 19 (8%) 2 (3%)
ER−and PR−/HER2− 64 (21%) 58 (25%) 6 (8%)
Other 28 (9%) 16 (7%) 12 (15%) < 0.001
Clinical trial participant
yes 82 (26%) 57 (24%) 25 (32%)
no 227 (73%) 173 (74%) 54 (68%) 0.23
Unknown 3 (1%) 3 (1%) 0 (0%)
PI3K specific trial
yes 40 (13%) 17 (7%) 23 (29%)
no 42 (13%) 40 (17%) 2 (3%) <0.001
NA 230 (74%) 176 (76%) 54 (68%)
Recurrent disease
yes 195 (63%) 134 (58%) 61 (77%)
no 117 (38%) 99 (42%) 18 (23%) 0.002
Metastatic at diagnosis
yes 44 (14%) 29 (12%) 15 (19%)
no 266 (85%) 202 (87%) 64 (81%) 0.16
Unknown 2 (1%) 2 (0.1%) 0 (0%)

Note: "Unknown," "other," or "NA" not included in p value calculation.